Navigation Links
Biodel Reports Third Quarter Fiscal Year 2011 Financial Results
Date:8/4/2011

our ability to secure FDA approval for Linjeta™ and our other product candidates under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act; our ability to market, commercialize and achieve market acceptance for product candidates developed using our VIAdel™ technology; the progress or success of our research, development and clinical programs and the initiation and completion of our clinical trials; the possibility that patients taking Linjeta™ may experience more injection site discomfort than they experience with competing products; unexpected data that may result from our clinical trials and our research and development activities; our ability to protect our intellectual property and operate our business without infringing upon the intellectual property rights of others; our estimates of future performance; our ability to enter into collaboration arrangements for the commercialization of our product candidates and the success or failure of those collaborations after consummation, if consummated; the rate and degree of market acceptance and clinical utility of our products; our commercialization, marketing and manufacturing capabilities and strategy; our estimates regarding anticipated operating losses, future revenues, capital requirements and our needs for additional financing; and other factors identified in our most recent report on Form 10-Q for the quarter ended March 31, 2011.  The company disclaims any obligation to update any forward-looking statements as a result of events occurring after the date of this press release.Biodel Inc.
(A Development Stage Company)
Condensed Balance Sheets
(in thousands, except share and per share amounts)September 30,June 30,20102011(unaudited)ASSETSCurrent:Cash and cash equivalents$

22,922$

41,999Restricted cash15060Marketable securities, available for sale6,001—Taxes receivable11686Other receivables119Prepaid and other assets365497Total cu
'/>"/>

SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. BioDelivery Sciences Announces Completion of BEMA Buprenorphine Phase 3 Chronic Pain Study
2. Biodel to Raise $30 Million Through Registered Direct Offering
3. Biodel Inc. to Present at 29th Annual JPMorgan Healthcare Conference on January 13th, 2011
4. Biodel Announces Name Change for Lead Product Candidate
5. Dyadic International Reports 2011 Second Quarter Financial Results
6. Vermillion Reports Results for the Second Quarter 2011
7. ReportsnReports - Needle-Free Drug Delivery Market & Hospital-Acquired Infections (HAI) Diagnostics Market Reports
8. Dendreon Reports Second Quarter 2011 Financial Results
9. Cambrex Reports Second Quarter of 2011 Results
10. Jennerex Reports Positive Mechanistic Proof-of-Concept Clinical Trial Results Using JX-594 to Treat Metastatic Melanoma
11. Gen-Probe Reports Financial Results for the Second Quarter of 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2015)... DUBLIN , May 20, 2015 Research and ... addition of the "Top Technologies in HW_Technical Insights" ... division of this report evaluated technology trends in the ... trends that are likely to have an impact in ... depth analysis of the top 10 health and wellness ...
(Date:5/20/2015)... DUBLIN , May 19, 2015 Research and ... addition of the "Global Cell Therapy Market Outlook ... Utilization of cell therapy in tissue and regenerative medicine ... are no other options which could help in the ... in this segment but they are unable to form ...
(Date:5/20/2015)... 2015 The global genotyping market is ... the forecast period of 2015 to 2020 to reach ... in drug discovery and development process and to provide ... addition to this,heavy investments by key manufacturers to offer ... propelling market growth. Browse 113 market data tables & ...
(Date:5/20/2015)... Agricultural firm H.J. Baker & Bro., Inc. ... Tiger-Sul. Since the purchase of Tiger Industries and ... 2005, H.J. Baker has leveraged the innovation of the ... portfolio of product offerings and solutions expertise. The deal ... innovation of Tiger-Sul, transforming the company into a leading ...
Breaking Biology Technology:Top Technologies in the Health and Wellness Industry 2015 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 2Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 3Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 4Genotyping Market Growing at 22.3% CAGR to 2020: Research Based on Technology, Applications, Opportunities, Challenges and Key Players. 5Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 2Agricultural Firm H.J. Baker & Bro., Inc., Celebrates 10 Years Since Acquisition Of Tiger-Sul 3
... ... DGV databases enable researchers to quickly and effectively use these invaluable resources. , ... Seattle, WA (PRWEB) July 16, 2009 -- ... (GAD) and Database of Genomic Variants (DGV). The dbGaP resource is ...
... WILMINGTON, Del., July 15 ParagonRx, a healthcare consulting ... has filed its interim analysis of a study that shows ... of opioid drugs meet FDA standards for risk evaluation and ... to the FDA during public hearings earlier this year. , ...
... - Scientists in Atlantic Canada have found a gene that ... the genetic cause of a rare disorder known as cutis ... feet and face to be loose and older looking, as ... brain. In the process, researchers found some interesting correlations with ...
Cached Biology Technology:New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix 2New and Updated Online Tutorials for dbGaP, GAD, and DGV from OpenHelix 3Canadian researchers discover gene related to the appearance of aging 2
(Date:5/21/2015)... 2015 The Sync Project™ , a ... health, today announced a collaborative partnership with Berklee,s ... center on collaboration on original research, joint course development ... the collaboration, The Sync Project and BerkleeICE are exploring ... in the 2015-2016 academic year.  The ...
(Date:5/19/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/18/2015)... Fingerprint Cards (FPC) has received an ... and FPC1035 from one if its module partners. Deliveries are ... 2015 and the sensors will be used by smartphone manufacturers ... 2015 hereby amount to 740 MSEK to date. In addition ... and a number of smaller orders not separately communicated amounting ...
Breaking Biology News(10 mins):The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 2The Sync Project Announces Partnership with Berklee College of Music's Institute for Creative Entrepreneurship 3Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... drugs, such as Famotidine, Cimetidine and Ranitidine, approved in the ... the fetus according to a large collaborative cohort study by ... published in the Journal of Clinical Pharmacology provides ... blocker drugs are given to women to relieve acid ...
... This release is available in French . ... over 12 million people worldwide, with more than 2 million new ... the parasite survives inside human cells. That mystery has now been ... by a team led by Dr. Martin Olivier a ...
... cell division, whether hematopoietic stem cells (HSCs) will develop ... blood cells depends on a chemical process called DNA ... laboratory of Dr. Frank Rosenbauer of the Max Delbrck ... the laboratory of Professor Sten Eirik W. Jacobsen (Lund ...
Cached Biology News:Heartburn drugs deemed safe for fetuses according to Ben-Gurion University researchers 2Major discovery opens door to leishmania treatment 2MDC scientists show how hematopoietic stem cell development is regulated 2
Human FADD Affinity Purified Polyclonal Ab...
Human VEGF R3/Flt-4 Phycoerythrin MAb (Clone 54733)...
Immunogen: Synthetic Peptide: V(22) N G H E F E I E G E G E G R(36) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human beta IG-H3 MAb (Clone 348506) Keywords: BIGH3, betaIG-H3 Protein Family: Extracellular Matrix Molecules...
Biology Products: